Kolko Miriam, Koch Jensen Peter
Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Acta Ophthalmol. 2017 Jun;95(4):370-373. doi: 10.1111/aos.13355. Epub 2017 Feb 22.
To compare various characteristics of Xalatan and five generic latanoprost ophthalmic solutions.
Drop size, volume, pH values, buffer capacity, viscosity, hardness of bottles and costs were determined. Drop sizes were measured in triplicates by micropipettes, and the number of drops counted in three separate bottles of each generic product was determined. pH values were measured in triplicates by a calibrated pH meter. Buffer capacity was exploited by titrating known quantities of strong base into 2.5 ml of each brand and interpolated to neutral pH. Kinematic viscosity was determined by linear regression of timed gravity flow from a vertical syringe through a 21-G cannula. The hardness of the bottles was evaluated by gradually increasing tension on a hook placed around each bottle until a drop was expelled reading the tension on an attached spring scale.
Drop sizes and the number of drops in the bottles varied significantly between the generic drugs. The control value of pH in the brand version (Xalatan ) was markedly lower compared to the generic latanoprost products. Titration of Xalatan to neutrality required substantially more NaOH compared to the generic latanoprost products. Finally, the viscosity revealed a significant variability between brands. Remarkable differences were found in bottle shapes, bottle hardness and costs of the latanoprost generics.
Generic latanoprost eye drops should not be considered identical to the original brand version as regards to drop size, volumes, pH values, buffer capacity, viscosity, hardness of bottles and costs. It is likely that these issues affect compliance and intraocular pressure (IOP)-lowering effect. Therefore, re-evaluation of the requirements for introducing generic eye drops seems reasonable.
比较适利达与五种通用型拉坦前列素眼药水的各项特性。
测定滴液大小、体积、pH值、缓冲容量、粘度、瓶子硬度及成本。用微量移液器对滴液大小进行三次测量,并确定每种通用产品三个独立瓶子中的滴数。用校准后的pH计对pH值进行三次测量。通过向2.5毫升各品牌产品中滴定已知量的强碱并内插到中性pH来测定缓冲容量。通过对垂直注射器中定时重力流经21G套管的情况进行线性回归来测定运动粘度。通过逐渐增加套在每个瓶子上的钩子的张力直至挤出一滴,读取附着弹簧秤上的张力来评估瓶子的硬度。
通用药物之间的滴液大小和瓶子中的滴数差异显著。与通用型拉坦前列素产品相比,品牌产品(适利达)的pH对照值明显更低。与通用型拉坦前列素产品相比,将适利达滴定至中性需要更多的氢氧化钠。最后,各品牌之间的粘度存在显著差异。在拉坦前列素仿制药的瓶子形状、瓶子硬度和成本方面发现了显著差异。
在滴液大小、体积、pH值、缓冲容量、粘度、瓶子硬度和成本方面,通用型拉坦前列素眼药水不应被视为与原品牌产品相同。这些问题可能会影响依从性和降低眼压(IOP)的效果。因此,重新评估引入通用型眼药水的要求似乎是合理的。